COMMUNIQUÉS West-GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025
19/08/2025
Aggregated presentation by day and by market Statement of transactions in own shares from August 11th to August 15th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
19/08/2025
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
19/08/2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
19/08/2025
Patent strengthens intellectual property for investigational new drug MTX-001 — Phase 2 clinical trial for chronic venous leg ulcers ongoing RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Merakris [...]
Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
19/08/2025
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment. 1 - 4 Initial cases have now been performed in Japan [...]
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
19/08/2025
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical [...]
Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science
19/08/2025
First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers The Company recently announced the results from its Phase II placebo- [...]
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
19/08/2025
- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Angitia [...]
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
19/08/2025
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( [...]
Aveanna to Participate at the Deutsche Bank Healthcare Summit
19/08/2025
ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Healthcare Summit in New York on September 10 [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
19/08/2025
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
19/08/2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window - [...]
Milestone® Pharmaceuticals to Present at Upcoming Conferences
19/08/2025
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo [...]
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
19/08/2025
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
19/08/2025
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”), a medical device [...]
Aptitude Development Expands Partnership with Counslr to Offer 24/7 Mental Health Support Across All Properties Nationwide
19/08/2025
Unlimited, 24/7 text-based mental health support available to student residents as demand for wellness amenities grows NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Counslr , a leading B2B mental health and wellness [...]
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
19/08/2025
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a [...]
COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
19/08/2025
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient [...]
Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC
19/08/2025
NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics , Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with myeloproliferative [...]

Pages